drugset / Trial / NCT00734994

Mitomycin C With Hyperthermia and Intravesical Mitomycin C to Treat Recurrent Bladder Cancer

NCT00734994

Phase 0 Completed 15 enrolled Mark Dewhirst
NaSingle-groupOpen-labelTreatment

Summary

Hypothesis: In selected patients external hyperthermia will be used in combination with intravesical Mitomycin-C (MMC) to treat recurrent transitional cell carcinoma (TCC) of the bladder after local resection and standard adjuvant therapy and thus prevent or delay recurrence and the need for radical cystectomy.

Timeline

Start
2008-04
Primary completion
2011-02
Completion
2011-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Mitomycin C Other / unclassified 40 mg Intravenous